(Q33332252)

English

Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

Europe PubMed Central

Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Chang J

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

publication date

1 April 2000

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

36 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

S11-4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Understanding adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900259-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(99)00259-2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33332252&oldid=1985600594"